1. LBA-004Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. (24th June 2018) Authors: Bendell, J; Ciardiello, F; Tabernero, J; Tebbutt, N; Eng, C; Di Bartolomeo, M; Falcone, A; Fakih, M; Kozloff, M; Segal, N; Sobrero, A; Shi, Y; Roberts, L; Yan, Y; Chang, I; Uyei, A; Kim, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. (28th July 2018) Authors: de Vos, S; Swinnen, L J; Wang, D; Reid, E; Fowler, N; Cordero, J; Dunbar, M; Enschede, S H; Nolan, C; Petrich, A M; Ross, J A; Salem, A H; Verdugo, M; Agarwal, S; Zhou, L; Kozloff, M; Nastoupil, L J; Flowers, C R Journal: Annals of oncology Issue: Volume 29:Number 9(2018) Page Start: 1932 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗